Guardion Health Sciences, Inc.

DB:0QTA Stock Report

Market Cap: €6.7m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Guardion Health Sciences Past Earnings Performance

Past criteria checks 0/6

Guardion Health Sciences's earnings have been declining at an average annual rate of -26.2%, while the Personal Products industry saw earnings growing at 9.8% annually. Revenues have been growing at an average rate of 63.3% per year.

Key information

-26.2%

Earnings growth rate

36.4%

EPS growth rate

Personal Products Industry Growth8.7%
Revenue growth rate63.3%
Return on equity-77.5%
Net Margin-187.5%
Last Earnings Update30 Sep 2022

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Guardion Health Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:0QTA Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2211-21130
30 Jun 2211-22150
31 Mar 229-25140
31 Dec 217-25140
30 Sep 215-14120
30 Jun 212-13100
31 Mar 212-990
31 Dec 202-990
30 Sep 202-990
30 Jun 202-990
31 Mar 201-12100
31 Dec 191-1190
30 Sep 191-880
30 Jun 191-870
31 Mar 191-750
31 Dec 181-860
30 Sep 181-970
30 Jun 181-970
31 Mar 181-870
31 Dec 170-650
30 Sep 170-640
30 Jun 170-640
31 Mar 170-640
31 Dec 160-740
30 Sep 160-540
30 Jun 160-640

Quality Earnings: 0QTA is currently unprofitable.

Growing Profit Margin: 0QTA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0QTA is unprofitable, and losses have increased over the past 5 years at a rate of 26.2% per year.

Accelerating Growth: Unable to compare 0QTA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0QTA is unprofitable, making it difficult to compare its past year earnings growth to the Personal Products industry (9.6%).


Return on Equity

High ROE: 0QTA has a negative Return on Equity (-77.51%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/04/09 14:07
End of Day Share Price 2023/01/10 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Guardion Health Sciences, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WooAscendiant Capital Markets LLC
Anthony VendettiMaxim Group